



Step Pharma to Present Promising Data on the Therapeutic Potential of Selective Small Molecule Inhibition of CTPS1 at the European Hematology Association Congress 2022

St. Genis-Pouilly, France, 30 May - Step Pharma, a biotech company developing CTPS1 inhibitors for the safe and effective treatment of cancer, announces today that it will be presenting data on its lead candidate STP938 at the European Hematology Association Congress being held from the 9-17 June, 2022 in Vienna, Austria.

Step Pharma will present three posters on STP938, its potent and highly selective small molecule inhibitor of CTPS1 and its potential as a therapeutic for the treatment of T Cell cancers, Multiple Myeloma and Graft-versus-Host Disease (GvHD).

Full details of the posters are:

Poster presentation: *CTPS1 is a novel therapeutic target in myeloma - selective small molecule inhibition delivers single agent activity and synergises with ATR inhibition*

Authors: Christina Pfeiffer, Philip Beer, H  l  ne Asnagli, Arnold Bolomsky, Alexander Grandits, Anja Schneller, Julia Huber, Niklas Zojer, Martin Schreder, Andrew Parker, Heinz Ludwig

Date and Time: Available from June 10, 09:00 CEST and on-demand until Monday, August 15, 2022, on the Congress platform

Session title: Myeloma and other monoclonal gammopathies - Biology & Translational Research

Poster Presentation: *CTP synthase 1 is a novel target in T cell cancers, with small molecule inhibition inducing death of neoplastic human T cells in vitro and inhibition of their growth in an in vivo xenotransplant model*

Authors: Philip Beer, H  l  ne Asnagli, Norbert Minet, Eef Hoeben, Andrew Parker, Alain Fischer, Sylvain Latour

Date and Time: Available from June 10, 09:00 CEST and on-demand until Monday, August 15, 2022, on the Congress platform

Session title: Lymphoma Biology & Translational Research

Poster Presentation: *Selective small molecule inhibition of CTP synthase 1 (CTPS1) suppresses T cell proliferation and cytokine release, highlighting a novel therapeutic target for graft-versus-host disease*

Authors: Philip Beer, Andrew Parker, H  l  ne Asnagli

Date and Time: Available from June 10, 09:00 CEST and on-demand until Monday, August 15, 2022, on the Congress platform

Session title: Stem cell transplantation – Experimental

-Ends-

About Step Pharma

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of oncology. The company has identified several inhibitors of CTPS1, with the most advanced, STP938, being prepared for clinical studies in haematological malignancies.

Step Pharma was founded in June 2014 by Kurma Partners, the Imagine Institute, and Sygnature Discovery based on the scientific discoveries of Dr Sylvain Latour and Prof. Alain Fischer (UMR1163 Inserm unit). Step Pharma is based in St. Genis-Pouilly, France and supported by a strong investor base led by Kurma Partners and including Bpifrance (Fonds Biothérapies Innovantes et Maladies Rares and InnoBio2 Fund), Pontifax, Hadean Ventures, Sunstone Life Science Ventures, Inserm Transfert Initiative, Idinvest, Sygnature Discovery and the Imagine Institute. More information on the company can be found at www.step-ph.com.

For more information please contact:

Consilium Strategic Communications

Amber Fennell, Allison Connolly, Stella Lempidaki
steppharma@consilium-comms.com